

Aerocrine

Press release
October 29, 2010

Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in the Financial Instruments Trading Act, it is hereby announced that subscription by exercise of subscription rights in the rights issue in Aerocrine has increased the number of shares and votes in Aerocrine during October 2010 as specified in the table below.

Number of shares and votes	
Before subscription	82 724 026
Increase	18 174 161
After subscription	100 898 187

Solna on October 29, 2010
Aerocrine AB (publ.)

For further information, please contact:
Michael Colérus, CFO, +46 8 629 07 85

About Aerocrine

Aerocrine AB (publ.) is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine is required to disclose the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on October 29, 2010.